Clinical Trial

A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a single-arm, multi-center, open-label, phase 2 study to evaluate the efficacy and safety of ICP-248 in subjects with relapsed or refractory mantle cell lymphoma.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-07-23; most recent amendment 2026-07-22.
Status change: Not Yet Recruiting → Recruiting 2025-08-26
Trial Details
NCT Number NCT07082686
Lead Sponsor Beijing InnoCare Pharma Tech Co., Ltd.
Conditions Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Enrollment 75 participants
Start Date 2025-08-21
Primary Completion 2027-12 (estimated)
Study Completion 2028-07 (estimated)
Updated on ClinicalTrials.gov 2026-07-23